Solid Neoplasm

In a phase1 trial, patients with an advanced solid tumor harboring aberrations in DNA damage repair genes including ATM were treated with ATR inhibitor BAY 1895344. Among 10 patients with ATM loss of … (full text at CIViC)

Open in CIViC

In this phase II basket trial (TAPUR), response to olaparib treatment was examined in four cohorts with ATM mutations. In the histology pooled cohort (36 evaluable patients) comprised of 19 different … (full text at CIViC)

PMID 41538762 · Carrizosa et al., 2026 · Open in CIViC

RAF inhibitor vemurafenib failed to inhibit ERK signaling in tumor cells and NIH3T3 that express class 3 BRAF mutations (G466V, G466E, D594G, D594N, and G596R).

PMID 28783719 · Yao et al., 2017 · Open in CIViC

RAF inhibitor vemurafenib failed to inhibit ERK signaling in tumor cells and NIH3T3 that express class 3 BRAF mutations (G466V, G466E, D594G, D594N, and G596R).

PMID 28783719 · Yao et al., 2017 · Open in CIViC

RAF inhibitor vemurafenib failed to inhibit ERK signaling in tumor cells and NIH3T3 that express class 3 BRAF mutations (G466V, G466E, D594G, D594N, and G596R).

PMID 28783719 · Yao et al., 2017 · Open in CIViC

When transferred into EGFR expressing HEK293 cells, BRAF L525R induced increased ERK phosphorylation to a level similar to that induced by BRAF V600E. ERK phosphorylation enhanced by BRAF L525R was no… (full text at CIViC)

PMID 28972961 · Shinozaki et al., 2017 · Open in CIViC

BRAF β3-αC deletions (BRAF N486_P490del, del T488_P492del, or P490_Q494del) are kinase-activating alterations, independent of CRAF and dimerization. Theses BRAF deletions are activating through restr… (full text at CIViC)

PMID 26996308 · Foster et al., 2016 · Open in CIViC

BRAF β3-αC deletions (BRAF N486_P490del, del T488_P492del, or P490_Q494del) are kinase-activating alterations, independent of CRAF and dimerization. Theses BRAF deletions are activating through restr… (full text at CIViC)

PMID 26996308 · Foster et al., 2016 · Open in CIViC

In a phase II basket trial (NCI-MATCH), patients with solid tumors or hematologic malignancies harboring BRAF non-V600 mutations were treated with trametinib. Among 50 patients assigned, 32 were eligi… (full text at CIViC)

PMID 31924734 · Johnson et al., 2020 · Open in CIViC

In this trial, patients with advanced rare tumours harbouring BRAF V600E mutations were treated with a combination of dabrafenib and trametinib. The study included eight distinct cohorts: anaplastic t… (full text at CIViC)

PMID 37059834 · Subbiah et al., 2023 · Open in CIViC

Across all TAPUR cohorts combined (n = 116 evaluable; BC n = 26, BTC n = 18, LC n = 25, UC n = 15, and additional solid tumors with low accural n = 32), patients with advanced solid tumors harboring B… (full text at CIViC)

PMID 41100773 · Al Baghdadi et al., 2025 · Open in CIViC

In the phase 1/2 clinical trial NCT03037385, one arm assessed the therapeutic benefit of the selective RET inhibitor pralsetinib across a range RET fusion positive solid tumors, excluding NSCLC and th… (full text at CIViC)

PMID 35962206 · Subbiah et al., 2022 · Open in CIViC

Next generation sequencing was performed on 35023 Chinese cases with 13 different solid tumor types. EGFR Fusions were detected in 106 samples. All EGFR fusions contained the complete tyrosine kinase … (full text at CIViC)

PMID 39054543 · Zhang et al., 2024 · Open in CIViC

In this phase 2 clinical trial, 267 patients with HER2 expressing solid tumours received Trastuzumab Deruxtecan. The cohort included patients with locally advanced, unresectable, or metastatic solid c… (full text at CIViC)

PMID 37870536 · Meric-Bernstam et al., 2024 · Open in CIViC

In this phase 1 dose-escalation study seventy patients with metastatic solid tumours were enrolled. Eight patient tumours were found to harbour NTRK gene fusions, six of which were ETV6-NTRK3. Treatme… (full text at CIViC)

PMID 30624546 · Hong et al., 2019 · Open in CIViC

In the phase 1/2 clinical trial NCT03037385, one arm assessed the therapeutic benefit of the selective RET inhibitor pralsetinib across a range RET fusion positive solid tumors, excluding NSCLC and th… (full text at CIViC)

PMID 35962206 · Subbiah et al., 2022 · Open in CIViC

In an in vitro study of gastrointestinal tumors, the HEK-293 cells expressing KIT V559D (a known sensitizing mutation to dasatinib) and T670I co-mutation was found to have reduced sensitivity to dasat… (full text at CIViC)

PMID 16046538 · Carter et al., 2005 · Open in CIViC

In an in vitro study of gastrointestinal tumors, HEK-293 cells expressing KIT V559D mutation were found to have sensitivity to dasatinib treatment. (IC50: 8nM). Sensitivity was determined by assessin… (full text at CIViC)

PMID 16046538 · Carter et al., 2005 · Open in CIViC

In cell lines, MRTX849 inhibits growth and viability of cells harboring KRAS G12C mutations, but not in cells with other mutant forms or of wild-type KRAS. In animal models, MRTX849 demonstrates anti… (full text at CIViC)

Open in CIViC

One patient was identified with a LMNA-NTRK1 positive tumor in this Phase I study (NCT02122913), which involved 70 heavily pretreated patients with a median age of 59.5 years, with multiple solid tumo… (full text at CIViC)

PMID 30624546 · Hong et al., 2019 · Open in CIViC

In this trial, 101 patients with solid tumours, including lung, prostate, sarcoma, melanoma, and breast cancer, harbouring LRP1B alterations were treated with immune checkpoint inhibitors. Most patien… (full text at CIViC)

PMID 33653800 · Brown et al., 2021 · Open in CIViC

In this phase 1 trial, 80 patients harbouring MTAP deletions/CDKN2A deletions received AMG 193 in a dose escalation study. The most common tumour types were PDAC (23.8%), NSCLC (17.5%), biliary tract … (full text at CIViC)

PMID 39293516 · Rodon et al., 2024 · Open in CIViC

Sequencing data from 22 human kidney cancer cases was used to identify the activating mechanisms conferred by mTOR mutations. Cells that expressed activating mTOR mutants were sensitive to rapamycin t… (full text at CIViC)

PMID 27482884 · Xu et al., 2016 · Open in CIViC

Sequencing data from 22 human kidney cancer cases was used to identify the activating mechanisms conferred by mTOR mutations. Cells that expressed activating mTOR mutants were sensitive to rapamycin t… (full text at CIViC)

PMID 27482884 · Xu et al., 2016 · Open in CIViC

Sequencing data from 22 human kidney cancer cases was used to identify the activating mechanisms conferred by mTOR mutations. Cells that expressed activating mTOR mutants were sensitive to rapamycin t… (full text at CIViC)

PMID 27482884 · Xu et al., 2016 · Open in CIViC

In this study, 30 patients with advanced solid malignancies harboring mTOR/AKT/PI3K pathway alterations were treated with Sapanisertib. The tumor types included sarcomas, breast, ovarian, head and nec… (full text at CIViC)

PMID 38126764 · Subbiah et al., 2024 · Open in CIViC

Sequencing data from 22 human kidney cancer cases was used to identify the activating mechanisms conferred by mTOR mutations. Cells that expressed activating mTOR mutants were sensitive to rapamycin t… (full text at CIViC)

PMID 27482884 · Xu et al., 2016 · Open in CIViC

Sequencing data from 22 human kidney cancer cases was used to identify the activating mechanisms conferred by mTOR mutations. Cells that expressed activating mTOR mutants were sensitive to rapamycin t… (full text at CIViC)

PMID 27482884 · Xu et al., 2016 · Open in CIViC

In this NCI-MATCH trial, 47 patients harboring codon 12, 13, or 61 NRAS mutated refractory solid tumors were treated with binimetinib. Of the 47 patients, >50% of the patients had metastatic colorecta… (full text at CIViC)

PMID 33637626 · Cleary et al., 2021 · Open in CIViC

In a first in human open label phase 1 dose escalation and expansion study of lifirafenib in advanced solid tumors (NCT02610361; n = 131; BRAF-mutated n = 53, KRAS/NRAS-mutated n = 66; biomarker BRAF … (full text at CIViC)

PMID 32182156 · Desai et al., 2020 · Open in CIViC

In a phase I study of larotrectinib in 67 patients with solid tumours, 8 patients were recorded as having objective response. 7 of these harboured NTRK fusions, and one had a NTRK1 amplification. This… (full text at CIViC)

PMID 30624546 · Hong et al., 2019 · Open in CIViC

Patients with solid tumor that have a NTRK fusion were treated with larotrectinib. NTRK mutations were detected in patients with acquired resistance.

Open in CIViC

Patients with solid tumor havoring NTRK fusion were treated with Larotrectinib. NTRK1 G595R mutation was deteceted in the tumor with acquired resistance. This patient was successfully treated with LOX… (full text at CIViC)

Open in CIViC

In a phase I study of larotrectinib in 67 patients with solid tumours, 8 patients were recorded as having objective response. 7 of these harboured NTRK fusions, and one had a NTRK1 amplification. This… (full text at CIViC)

PMID 30624546 · Hong et al., 2019 · Open in CIViC

In this Phase I study (NCT02122913), which involved 70 heavily pretreated patients with a median age of 59.5 years, with multiple solid tumor types, None of the patients with NTRK point mutations had … (full text at CIViC)

PMID 30624546 · Hong et al., 2019 · Open in CIViC

In the LOXO-TRK-14001 trial, all eight patients with TRK-fusion positive cancer had objective response to larotrectinib. The FDA approval for this indication excludes patients with known resistance mu… (full text at CIViC)

PMID 30624546 · Hong et al., 2019 · Open in CIViC

Patients with solid tumor that have a NTRK fusion were treated with larotrectinib. NTRK mutations were detected in patients with acquired resistance.

Open in CIViC

Patients with solid tumor havoring NTRK fusion were treated with Larotrectinib. NTRK3 G623R mutation was deteceted in the tumor with acquired resistance. This patient was successfully treated with LOX… (full text at CIViC)

Open in CIViC

In this Phase I study (NCT02122913), which involved 70 heavily pretreated patients with a median age of 59.5 years, with multiple solid tumor types, None of the patients with NTRK point mutations had … (full text at CIViC)

PMID 30624546 · Hong et al., 2019 · Open in CIViC

In one arm of this phase 1b study, 7 patients with PTEN deficient tumors were treated with continuous buparlisib (100 mg/daily) orally plus standard dose carboplatin AUC 5 and paclitaxel 175 mg/m2. No… (full text at CIViC)

PMID 28281183 · Smyth et al., 2017 · Open in CIViC

560 of 37,056 patients from hospitals across China were found to contain RET mutations with the prevalence highest in thyroid cancer (6.45%), mediastinal tumor (7.69%), uterine cancer (3.94%), urinary… (full text at CIViC)

PMID 32284345 · Zhao et al., 2020 · Open in CIViC

560 of 37,056 patients from hospitals across China were found to contain RET mutations with the prevalence highest in thyroid cancer (6.45%), mediastinal tumor (7.69%), uterine cancer (3.94%), urinary… (full text at CIViC)

PMID 32284345 · Zhao et al., 2020 · Open in CIViC

In this non-randomized phase 2 KEYNOTE-158 trial 1066 patients with solid tumours and tumour mutation burden (TMB) >=10 mutations/Mb were treated with anti-PD1 antibody pembrolizumab. Of 790 patients … (full text at CIViC)

PMID 32919526 · Marabelle et al., 2020 · Open in CIViC

A retrospective analysis from three cancer centres in China examined the use of pembrolizumab, as monotherapy or combined with chemotherapy, in 116 patients with MSI-high or TMB-high advanced solid tu… (full text at CIViC)

PMID 38451314 · Yan et al., 2024 · Open in CIViC

This study analyzed over 300 patient with advanced solid tumors and melanoma across 22 tumor types from four KEYNOTE clinical trials to define genomic and immune predictors of response to pembrolizuma…

This was a Phase 1/2 study in which 55 patients between 4 months and 76 years of age with TRK-fusion positive tumors were given NTRK inhibitor Larotrectinib. Patients had 17 unique NTRK fusion type… (full text at CIViC)

PMID 29466156 · Drilon et al., 2018 · Open in CIViC

This Phase I study (NCT02122913) enrolled 70 heavily pretreated adult patients (median age 59.5 years) with various advanced solid tumors. Among them, one patient was identified with a TPR::NTRK1 fusi… (full text at CIViC)

PMID 30624546 · Hong et al., 2019 · Open in CIViC

This study describes two novel PLAG1 fusions, TRPS1–PLAG1 and NDRG1–PLAG1, identified in histologically confirmed cases of chondroid syringoma. Both fusions involve promoter swapping, placing PLAG1 ex… (full text at CIViC)

PMID 32345665 · Panagopoulos et al., 2020 · Open in CIViC

Describes a meta-analysis of three separate phase I or II trials: ALKA-372-001, STARTRK-1, and STARTRK-2. All of these evaluate entrectinib in NTRK fusion-positive solid tumours. 31/54 had objective r… (full text at CIViC)

PMID 31838007 · Doebele et al., 2020 · Open in CIViC

The overall safety and antitumor activity of entrectinib was described for two phase I trials of patients with advanced solid tumors harboring NTRK1/2/3, ROS1, or ALK gene fusions. NTRK1 fusions were … (full text at CIViC)

PMID 28183697 · Drilon et al., 2017 · Open in CIViC